Literature DB >> 4829529

Fibrin-fibrinogen degradation products in cerebrospinal fluid of patients admitted to a psychiatric unit.

R Hunter, T Thomson, C M Reynolds, P M Pitcher.   

Abstract

Paired cerebrospinal fluid (CSF) and serum samples collected from 81 of 241 patients admitted to a district psychiatric hospital during a six month period were assayed for fibrin/fibrinogen degradation products (FDP) using a haemagglutination inhibition technique. FDP were found in all serum samples. Fifteen patients (18·5%) had FDP in the CSF (range 0·7-3·75 μg/ml.) and of these 13 (87%) had associated CSF protein abnormalities and 9 (60%) were hypertensive. Mean serum FDP values were the same (4·4 μg/ml.) in patients with and without FDP in the CSF. Three patients had raised serum FDP concentrations but no FDP in the CSF. The evidence suggests that the presence of FDP in CSF indicates recent central nervous system damage. In this series the most common cause was vascular disease.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4829529      PMCID: PMC494636          DOI: 10.1136/jnnp.37.3.249

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

1.  Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products.

Authors:  A P FLETCHER; N ALKJAERSIG; S SHERRY
Journal:  J Clin Invest       Date:  1962-04       Impact factor: 14.808

2.  [Analysis, by immuno-chemical methods, of the degradation by plasmin of human fibrinogen and fibrin, at different stages].

Authors:  V NUSSENZWEIG; M SELIGMANN
Journal:  Nouv Rev Fr Hematol       Date:  1960 Nov-Dec

3.  Abnormal cerebrospinal fluid total protein and gamma-blobulin levels in 256 patients admitted to a psychiatric unit.

Authors:  R Hunter; M Jones; A Malleson
Journal:  J Neurol Sci       Date:  1969 Jul-Aug       Impact factor: 3.181

4.  Serum and urinary fibrin-fibrinogen degradation products in glomerulonephritis.

Authors:  A R Clarkson; M K MacDonald; J J Petrie; J D Cash; J S Robson
Journal:  Br Med J       Date:  1971-08

5.  Urinary fibrin-fibrinogen degradation poducts after renal homotransplantation.

Authors:  A R Clarkson; J B Morton; J D Cash
Journal:  Lancet       Date:  1970-12-12       Impact factor: 79.321

6.  Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment.

Authors:  C Merskey; G J Kleiner; A J Johnson
Journal:  Blood       Date:  1966-07       Impact factor: 22.113

7.  Fibrin degradation products in sera of normal subjects.

Authors:  P C Das; A G Allan; D G Woodfield; J D Cash
Journal:  Br Med J       Date:  1967-12-23

8.  Spontaneous fibrinolysis in pulmonary embolism.

Authors:  J E Wilson; E P Frenkel; A K Pierce; R L Johnson; E R Winga; G C Curry; D S Mierzwiak
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

9.  Serum fibrin-fibrinogen degradation products associated with postoperative pulmonary embolus and venous thrombosis.

Authors:  C V Ruckley; P C Das; A G Leitch; A A Donaldson; W A Copland; A T Redpath; P Scott; J D Cash
Journal:  Br Med J       Date:  1970-11-14
  9 in total
  5 in total

1.  Fibrin-fibrinogen degradation products in cerebrospinal fluid.

Authors:  M J Brueton; G R Breeze; J Stuart
Journal:  J Clin Pathol       Date:  1976-04       Impact factor: 3.411

2.  Childhood bacterial meningitis.

Authors:  R H Lye
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-02       Impact factor: 10.154

3.  Coagulation and fibrinolytic activity of cerebrospinal fluid.

Authors:  M Anderson; K B Matthews; J Stuart
Journal:  J Clin Pathol       Date:  1978-05       Impact factor: 3.411

4.  Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA).

Authors:  H Fodstad; I M Nilsson
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216

5.  Monitoring fibrinolytic activity in the cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: a guide to the risk of rebleeding?

Authors:  R S Maurice-Williams; Y B Gordon; A Sykes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-02       Impact factor: 10.154

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.